The test of your character is what it takes to stop you!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Momo starting to pick up for $GTBP back at the 1.56 range during power hour
$GTBP making a great move, almost at $1.60 which should theoretically act as a floor. Nothing in the way now, i love this ticker #Biotech
Immuno-oncology is the next big thing for big pharma! Now, biopharmaceutical companies such as $GTBP are making dramatic advances in an emerging area of research known as immuno-oncology. This marks a significant milestone in the battle against cancer. As the name implies, immuno-oncology marshals the human body’s own immune system to fight cancer. In many cases, immunotherapy is vastly preferable to conventional treatments. Survival rates are higher in several tumor types, and these medications have the potential to significantly extend lives. Treatments also can be deployed against a wide array of cancers. I believe immuno-oncology holds enormous promise for patients and significant opportunities for investors.
Nice move on $GTBP new hod one step closer to 1.60!!!
Support should move to the $1.60's soon and the next PR may send this right back over $2
$GTBP biotech advisors already on board: they are highly experienced and the best on their field ... would you be surprised if/when GT Biopharma starts getting real attention from some of these large biotechnology companies.
NEWS: Dr.Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company https://biotechstocks.com/gt-biopharma-inc-gtbp-announces-dr-raymond-w-urbanski-elevated-to-president-and-chief-medical-officer-of-the-company/ … via @Biotech Stocks | Biotechnology Investments and News. The Future of Innovation & Discovery.
OXS-3550 for liquid tumors. The TRiKE platform has shown promising in vivo data compared to
BiKEs . (The addition of Il-15 created NK cell proliferation resulting in 60-70% remission vs 30-
50% for BiKE)
OXS-4550 Again using the TRiKE platform In Vivo data isn't yet, however Dr. Miller assured me in
the email that they've made significant progress with it.
OXS-4235 There's a chance (albeit slim) that this Multiple Myeloma drugs enters the clinic this
year
Yeahh..Good to see you too NYC! If we see 1.80 break today and I think there's a nice push into $2 if anything, a decent short term swing this week. I think it's got long term potential with just the board alone in consideration.
With that new president & CMO of GTBP management jumping on board, offers tons of experience being involved with huge biotech companies before Pfizer This company offers value and gettin confidence from new investor as well...
GT Biopharma, Inc. is a biotechnology company focused on innovative drugs for the treatment of cancer. GT’s lead oncology drug candidate, OXS-1550 (DT2219) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or the CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. In addition, GTs TriKE platform will address a number of cancer types. GT’s nervous system platform is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for nervous system diseases (Neurology and Pain) and shepherding them through the approval process to the NDA. GT Biopharma’s neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.
Morning Blockchain!!! It's good to see you again!
4.30% up green $GTBP. Its a nice reversal from Tuesday.
Another green open for us. GTBP rebound in the works it looks like to me
Immuno-oncology, one of the pillars of cancer treatment, is driving engagement worldwide among biotech, large pharma, universities/cancer centers and the financial investment community. Currently, more than 130 biotech and 20 pharma companies are developing immuno-oncology therapies and GT Biopharma is one of a leading pharma company! $GTBP
I think an update would give it the push were waiting for, company has a lot of potential in its pipeline.$GTBP
OXS-3550 TriKE has been proven to superior to OXS-1550 in in vivo studies, so I don't expect OXS-1550 to pass Phase II trials, however OXS-3550 TriKE most likely will. As it has been proven to be more effective than Rituxan in killing cancer cells.
PainBrake will use a patented technology - and unique shape - that allows tablets to be easily broken into smaller, precise doses, for maximum dose flexibility and accuracy.
IMO we trade back up to 1.60s thinking tomorrow is going to be exciting!!!!!!!
Excellent Blockchain!!! The next step is to list on NASDAQ!!!
LOL I am all about "sprinting" but I'll take this uptrend today. Let's hope it continues. $GTBP
I agree volume this last week for GTBP has been consistently increasing IMO its only a matter of time before the price follows the same pattern and starts to increase as well...just a waiting game at this point
Volume looks good right now. We just need price to follow.
OXS-3550 TRiKe looks even more promising than OXS-1550
http://bispecific.com/wp-content/uploads/sites/90/2016/10/Vallera-TRiKEs.pdf
https://ash.confex.com/ash/2016/webprogram/Paper93724.html
http://stm.sciencemag.org/content/8/328/328ec35
To overcome the cancer problem, scientists at the Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, have generated a bispecific killer engager (BiKE) containing single-chain scFv against CD16 and CD33. The purpose was to create a so called immunologic synapse between NK cells and CD33(+) myeloid targets.
In advancing the treatment options, these scientists have now developed a second-generation anti-CD16-IL-15-anti-CD33 TriKE, a single-chain, tri-specific NK cell engager (TriKE), which incorporated a novel modified human IL15 crosslinker, producing a novel trispecific killer engager or TriKE to induce expansion, priming, and survival. The scientists believe that this approach will enhance clinical efficacy.
The TriKE platform technology, developed by Jeffrey Miller, Deputy Director of the Masonic Cancer Center, University of Minnesota, and his colleagues at the University of Minnesota, is designed to enhance the activity of Natural Killer (NK) cells. NK cells are a type of white blood cell which are an important component of the innate immune system and play a major role in the rejection of tumor and virally infected cells.
Honestly I think it’s got potential. $GTBP is the real deal and not some fly by night scam. They have bought out GTP, acquired Dr. Urbanski as President & CMO, acquired GTP's drugs, one of which is near NDA status, meaning revenue and no more dilution.
Great things to come after this promotion of Dr.Urbanski..the stock price will back to it's home.
Agreed. GTBP has way too much going on right now to ignore it...especially with the way companies are now promoting Dr. Urbanski to be President and Chief Medical Officer of the Company Could you imagine if GTBP getting reversal for today?
Dr. Daniel Vallera, the inventor of OXS-1550 and Director of the Section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, said he believes OXS-1550 will play an important role in the treatment of cancer. The drug is designed to identify certain cancer cells and kill them, without damaging healthy cells.
"We believe OXS-1550 to be a powerful alternative to existing chemotherapies, since many patients fail chemotherapy or reach the toxic limits of their therapy," Vallera said.
NOW we have seen the benefit of OXS-1550
Immuno-oncology is the next big thing for big pharma! Now, biopharmaceutical companies such as $GTBP are making dramatic advances in an emerging area of research known as immuno-oncology. This marks a significant milestone in the battle against cancer. As the name implies, immuno-oncology marshals the human body’s own immune system to fight cancer. In many cases, immunotherapy is vastly preferable to conventional treatments. Survival rates are higher in several tumor types, and these medications have the potential to significantly extend lives. Treatments also can be deployed against a wide array of cancers. I believe immuno-oncology holds enormous promise for patients and significant opportunities for investors.
GT Biopharma, Inc. is a biotechnology company focused on innovative drugs for the treatment of cancer. GT’s lead oncology drug candidate, OXS-1550 (DT2219) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or the CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. In addition, GTs TriKE platform will address a number of cancer types. GT’s nervous system platform is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for nervous system diseases (Neurology and Pain) and shepherding them through the approval process to the NDA. GT Biopharma’s neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.
Even it's below 1.60 now but it doesn't seem weak. $GTBP appears to be a relatively strong support level right now based on the overall number of shares sitting there for GTBP
Immuno-oncology is the next big thing for big pharma! Now, biopharmaceutical companies such as $GTBP are making dramatic advances in an emerging area of research known as immuno-oncology. This marks a significant milestone in the battle against cancer. As the name implies, immuno-oncology marshals the human body’s own immune system to fight cancer. In many cases, immunotherapy is vastly preferable to conventional treatments. Survival rates are higher in several tumor types, and these medications have the potential to significantly extend lives. Treatments also can be deployed against a wide array of cancers. I believe immuno-oncology holds enormous promise for patients and significant opportunities for investors.
IMHO- investors have a high degree of confidence in the particularly the biotech sub-sector. Keeping my eyes peeled, GTBP on the radar.
This company has a Great future. $ADAC
After starting production on a new B-52 aircraft landing gear contract, $ADAC is simultaneously producing the drag brace, which is a part of the landing gear assembly for the F16 fighter jet. Good job $ADAC
Agree! Nice tight spread this morning with 212,599 Bid support and a thin Ask! $ADAC
Gonna be some very "big" things happening with PAOG very soon. shorts and side-liners be careful here. PAOG is PRIMED FOR TAKE- OFF $$$$$
REAL CLINICS
REAL PATIENTS
REAL REVENUES = a REALLY HUGE PPS INCREASE $$$$$$$$
$PAOG volume is high today! Almost 2M Really like this stock for a Big Run. Upcoming catalyst.
Matter of time here....good one accumulate at these prices.$PAOG
Excited about trading this week in $PAOG because progress should be made on this company